Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · INTENSITY THERAPEUTICS, INC. (INTS)

Intensity Therapeutics Q2 net loss widens to $3.0 million; cash falls to $9.5 million

Negative Impact 3 of 5 earnings Written later

Intensity Therapeutics reported a second quarter 2026 net loss of $3.0 million, up from $2.5 million a year earlier, with no revenue reported. Cash and cash equivalents were $9.5 million as of June 30, 2026, and the company said it restarted resources-dependent trial activity, including resuming enrollment at limited U.S. sites in the Phase 3 INVINCIBLE-3 study, which increased costs.

Key points

  • Net loss was $3.0 million for Q2 2026 versus $2.5 million for Q2 2025.
  • Research and development expenses rose to $1.8 million from $1.5 million, mainly from higher INVINCIBLE-3 study costs.
  • Cash and cash equivalents were $9.5 million on June 30, 2026, down from $11.9 million at December 31, 2025.
  • The company raised $1.6 million net under its at-the-market facility in Q2 2026 and $1.3 million more after June 30, 2026.

The filing

CompanyINTENSITY THERAPEUTICS, INC. (INTS)
Form8-K, current report
Filed with the SECAug 11, 2026, 7:40 AM ET
Accession number0001567264-26-000061

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.